The BCORL1 Knockout A-549 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line, with targeted disruption of the BCORL1 gene. This loss-of-function model provides a heterogeneous pool of cells harboring diverse CRISPR-induced mutations in BCORL1, enabling robust assessment of gene function without clonal selection artifacts. The polyclonal format is particularly suited for pooled functional screens, dose-response studies, and assays where population-level responses to genetic perturbation are desired. By abrogating BCORL1 expression, researchers can interrogate its role in transcriptional regulation and tumor biology within a physiologically relevant epithelial context.
The host cell line, A-549, originates from the lung adenocarcinoma of a 58-year-old Caucasian male and serves as a well-established model for alveolar epithelial biology. These adherent cells retain features of type II pneumocytes and are extensively used in cancer research, drug metabolism investigations, and studies of respiratory pathologies. Their robust growth and reproducible culture conditions facilitate a broad range of molecular and cellular assays. A-549 cells harbor wild-type TP53 and exhibit moderate EGFR expression, making them a versatile platform for examining signaling crosstalk in non-small cell lung cancer contexts.
BCORL1 encodes a transcriptional corepressor that functions as a scaffold linking sequence-specific transcription factors, such as BCL6, to histone deacetylase (HDAC) complexes containing HDAC3, NCOR2 (SMRT), and CTBP1. This multiprotein assembly catalyzes histone deacetylation at target gene promoters, leading to chromatin compaction and transcriptional silencing. BCORL1 thereby negatively regulates genes involved in apoptosis and cell cycle progression, including TP53, CDKN1A (p21), BCL2, and MYC. Its activity is modulated by upstream inputs from BCL6 and NCOR family members, positioning BCORL1 at a node of pathways that control cell proliferation, survival, and differentiation. Disruption of BCORL1 is thus predicted to relieve repression of these downstream effectors, potentially altering cellular homeostasis.
In A-549 lung adenocarcinoma cells, BCORL1 knockout is expected to attenuate BCL6-mediated transcriptional repression, thereby influencing the expression of key tumor suppressors and oncogenes. This perturbation may shift the balance between proliferation and apoptosis, offering a model to study mechanisms of lung cancer initiation and progression. Given the involvement of BCORL1 in hematopoietic malignancies such as acute myeloid leukemia and myelodysplastic syndrome, this knockout platform also enables comparative oncogenic studies across tissue types. Furthermore, because A-549 cells are a workhorse for drug metabolism assays, the BCORL1-deficient polyclonal population can be employed to explore how this corepressor impacts chemosensitivity and resistance in lung epithelial malignancies.
Researchers can utilize this knockout model in a variety of experimental paradigms, including chromatin immunoprecipitation (ChIP-qPCR) to map histone modification changes, RNA-sequencing for transcriptome-wide analysis, and western blotting or RT-qPCR to quantify target gene expression. Functional assays such as apoptosis detection (annexin V staining, caspase activity) and cell viability measurements (MTT, CellTiter-Glo) are directly applicable to investigate BCORL1-dependent survival mechanisms. The polyclonal nature of the cells is advantageous for dose-response studies and pooled screening approaches. For further technical details or assistance, please contact Ascent Research.
